Insulin Bootcamp: Dosing, Monitoring, Titrating, and Care Coordination

Description

Good news: New and emerging insulin agents—including insulin glargine U-300, regular insulin U-500, and insulin degludec U-100 and U-200—expand therapeutic options, can increase medication adherence, reduce injection burden, and facilitate normal physiological function. The downside: The increasing number of products available complicates treatment decisions for patients, prescribers, pharmacists, and other health care professionals. In this case-based workshop, pharmacists will learn about the safe and effective use of new insulin products, including strategies to titrate insulin doses, safely switch insulin products, ensure care coordination, and provide practical advice to minimize hypoglycemia.

Pharmacist Learning Objectives

At the completion of this application-based activity, participants will be able to:

  1. Compare the characteristics of new insulin products available in the market.
  2. Demonstrate how to safely titrate and switch insulin products.
  3. Describe strategies to minimize insulin-induced hypoglycemia, including patient education tools.
  4. Discuss management strategies that ensure the coordination of diabetes care among patients switching between health care settings.
 
 

Supporter

This activity is supported by an independent educational grant from Novo Nordisk, Inc.

 
Speakers:
Stuart
Stuart Haines, PHARMD
Professor and Director, Pharmacy Professional Development
University of Mississippi School of Pharmacy
 
Joshua
Joshua Neumiller, PharmD, CDE, FAADE, FASCP
Vice-Chair & Associate Professor
WSU College of Pharmacy and Pharmaceutical Sciences
 
Learning Level: Level 3
Track: Pharmacist Clinical Patient Care Services, Ambulatory Care
Session Time Slot(s): 
Date: 
Sunday, March 24
Time: 
7:00 AM - 8:30 AM
Room: 
Washington State Convention Center - Room 606-607
ACPE Pharmacist: 0202-0000-19-056-L01-P
CEUs Pharmacist: .15
Activity Type:
Application-based